Pfizer – Non Small Cell Lung Cancer With ALK or ROS1 Rearrangement

Submitted By:
Published Date:
January 25, 2020

Access Program Information

This expanded access study has being designed following a demand from the FDA, given the
increase in the number of request for single patient INDs for lorlatinib

Rare Disease:
Spinal muscular atrophy